tailieunhanh - Báo cáo y học: "Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. | Available online http content 8 6 R167 Research article Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis Therese Vallerskog Mikael Heimburger Iva Gunnarsson Wei Zhou Marie Wahren-Herlenius Christina Trollmo and Vivianne Malmstrom Open Access Rheumatology Unit Department of Medicine Solna Karolinska Institutet CMM L8 04 Karolinska Hospital SE-171 76 Stockholm Sweden Contributed equally Corresponding author Christina Trollmo Received 29 Aug 2006 Revisions requested 25 Sep 2006 Revisions received 6 Oct 2006 Accepted 8 Nov 2006 Published 8 Nov 2006 Arthritis Research Therapy 2006 8 R167 doi ar2076 This article is online at http content 8 6 R167 2006 Vallerskog et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The objective of this study was to investigate the interaction between levels of BAFF B-cell activation factor of the tumour necrosis factor TNF family and APRIL a proliferation-inducing ligand and B-cell frequencies in patients with systemic lupus erythematosus SLE and rheumatoid arthritis RA treated with the B-cell-depleting agent rituximab. Ten patients with SLE were treated with rituximab in combination with cyclophosphamide and corticosteroids. They were followed longitudinally up to 6 months after B-cell repopulation. Nine patients with RA resistant or intolerant to anti-TNF therapy treated with rituximab plus methotrexate were investigated up to 6 months after treatment. The B-cell frequency was determined by flow cytometry and serum levels of BAFF and APRIL were measured by enzyme-linked immunosorbent assays. BAFF levels rose significantly .